Table 4.
Drug | Target/mechanism of action | Class | Company | Status | ClinicalTrials.gov |
---|---|---|---|---|---|
Eculizumab | C5 inhibition | mAb | Alexion Pharmaceuticals | Phase 2 ongoing; off-label use in clinic [161] | NCT03518203 (pediatric + adult) [162] |
Ravulizumab (ALXN1210) | C5 inhibition | mAb | Alexion Pharmaceuticals | Phase 3 ongoing |
NCT04543591 (adolescent + adult) [141] NCT04557735 (pediatric) [142] |
Nomacopan (Coversin) | C5 and LTB4 inhibition | Recombinant protein | Akari Therapeutics | Phase 3 ongoing | NCT04784455 (pediatric) [145] |
Narsoplimab (OMS721) | MASP-2 inhibition | mAb | Omeros Corporation | Phase 2 complete | NCT02222545 (adult) [147] |
HSCT-TMA Hematopoietic stem cell transplantation-associated thrombotic microangiopathy, LTB4 Leukotriene B4, mAb Monoclonal antibody, MASP-2 Mannan-binding lectin-associated serine protease 2